Glycated Albumin Market In-depth Research & Key Company Profiles are Lifespan Biosciences, Biomatik Corporation, Abbexa, G Biosciences, DRG International

Increasing approval of novel glycated albumin test kits by key players in the market is expected to expand glycated albumin market size in the near future. For instance, in 2017, Japan-based Asahi Kasei Pharma Corporation received 510(k) clearance from the U. S. Food and Drug Administration (FDA) for its new Lucica Glycated Albumin-L, which is an in vitro diagnostic assay kit formulated for the U.S market.

Lucica Glycated Albumin-L is developed for the quantitative measurement of glycated albumin in human serum on compatible clinical chemistry analyzers. The approval of novel glycated albumin test kits from major regulatory bodies is expected to fuel glycated albumin kits/assays market growth over the forecast period.

Furthermore, increasing prevalence of diabetes is expected to increase the demand for glycated albumin test, thereby driving growth of the global glycated albumin assays market. For Instance, according to the data published by the World Health Organization (WHO), in 2014, around 8.5% of the adults aged 18 and above accounting around 422 million adults were suffering from diabetes worldwide. According to a survey conducted by the Center for Disease Control and Prevention (CDC), in 2016, over 30.3 million people in the U.S. were diagnosed with diabetes, which accounts for around 9% of the U.S. population. Such high prevalence of diabetes globally will increase the demand for glycated albumin and therefore, is expected to drive the market growth.

Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1957

The global glycated market is expected to exhibit a CAGR of XX% over the forecast period (2018 – 2026), owing to increasing approval of novel glycated albumin kits by major regulatory bodies in the key regions

North America held dominant position in the global glycated albumin market and is expected to retain its dominance over the forecast period (2018 – 2026), owing to the approval of novel glycated albumin test in the region. For instance, in 2017, Asahi Kasei Pharma Corporation received the U.S. Food and Drug Administration 510(k) clearance for its Lucica Glycated Albumin-L, which is an in vitro diagnostic assay kit formulated for the U.S market.

Asia Pacific is expected to witness significant growth over the forecast period due to increasing prevalence of diabetes in emerging economies such as India, Japan, and China. For instance, according to a survey conducted by the National Institute of health (NIH), in 2016, over 62 million people were diagnosed with diabetes in India.

Glycation is the process of bonding of a sugar molecule. For instance, glucose to a protein or a lipid molecule such as albumin. Glycated albumin is glucose bonded to an albumin molecule. Protein molecule i.e. albumin is present in the blood, major body organs, and body fluids. Function of albumin is to maintain shape of the cell and distribute hormones and nutrients.

The amount of albumin decreases in the body when blood glucose levels are low, whereas increases when blood glucose levels are high. Glycated albumin is measured during initiation of diabetes therapies to determine medication dose for treatment of diabetes. According to a study conducted by American Association for Clinical Study, in 2011, glycated albumin is described as a novel biomarker for the detection and management of diabetes. Treatment of diabetes requires glycemic control. There are various measurements used to provide indicators, which include glycated hemoglobin (HbA1c), 1, 5-anhydroglucitol (1,5AG), and glycated albumin.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1957

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave

This release was published on openPR.